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MITOCHONDRIAL DYSREGULATION: EARLY WARBURG EFFECT AS A 
MEANS OF RISK STRATIFICATION IN COLON CANCER 
BILAL LATIF 
ABSTRACT There! exists! a! profound! need! for! biomarkers! that! will! allow! for! better!screening!and!risk!stratification!for!colorectal!cancer!(CRC).!With!the!advent!of!the!newly!termed!“metabolic!syndrome”,!CRC!prevalence!is!trending!upwards!even!with!much!improved!screening!protocols!and!remains!the!second!leading!cause!of!cancer!related!morbidity.!The!“metabolic!syndrome”!refers!to!a!range!of!environmental!risk!factors,! including!diabetes!and!obesity,! thought! to!be! increasing! the!prevalence!of!CRC.! An! altered!metabolism! is! seen! in!metabolic! syndrome,! which! affects! cancer!through! changes! in! the! relationship! between! glycolysis,! the! Krebs! cycle,! and!mitochondrial! oxidative! phosphorylation! (OXPHOS).! Specifically,! it! has! been!observed! that! highly! proliferative! tumorigenic! cells! are! undergoing! a! shift! away!from! the! energy! efficient! OXPHOS! and! toward! aerobic! glycolysis! even! under!normoxic! conditions.! This! effect! has! been! termed,! the! Warburg! Effect.! As! a!consequence! of! endogenous! (e.g.! genetic,! diabetes! etc.)! and! exogenous! (e.g.! diet,!smoking! etc.)! factors,! alterations! in! cell! proliferation/death! have! been! shown! to!occur! throughout! the! colon! reflecting! the! diffuse! “field! of! injury”! (field!carcinogenesis).! !Also!due!to!high!energy!demands!it! is!recognized!that!the!hyperOproliferative!mucosa! contiguous! to! colonic! tumors!may! be! hyperOmetabolic.! ! Our!
!! v 
group!has!been!interested!in!elucidating!the!biological!nature!of!field!carcinogenesis!and! assesses! expression! of! key! metabolic! markers! in! the! rectal! biopsies! from!patients!who!harbor!neoplasia!elsewhere!in!their!colon.! !We!found!key!indications!of! a! glycolytic! shift! toward! aerobic! glycolysis! with! upregulation! of! glucose!transporter!(GLUT1)!as!well!as!pyruvate!shunting!away!from!OXPHOS!via!pyruvate!kinase!muscle!2!(PKM2).!These!changes!were!further!corroborated!by!an!increase!in!hypoxia! inducible! factor! 1! alpha! (HIF1α),! which! is! normally! seen! to! increase!glycolytic! function! in! hypoxic! conditions.! Along! with! these! glycolytic! changes! we!also! found! mitochondrial! dysfunction! in! patients! with! adenomas.! Specifically,!mitochondrial!mass!was!found!to!be!increased,!with!increases!in!mtDNA!as!well!as!upregulation! of! mitochondrial! fusion! via! optic! atrophy! 1! (OPA1).! Uncoupling!protein!2,!which!decouples!OXPHOS! from!ATP!synthesis! in! the!mitochondria,!was!also!found!to!be!upregulated.!These!findings!represent!a!novel!panel!of!biomarkers!for!assessing!CRC!risk!via!analysis!of!metabolic!dysfunction!in!the!easily!accessible!rectal!epithelium.!  
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INTRODUCTION 
 
Despite many recent innovations in testing procedures and practices, colorectal 
cancer (CRC) remains the second leading cause of cancer related mortality in the United 
States. This year alone there are estimated to be 93,090 new cases as well as 49,700 
deaths due to colon cancer (Siegel, Miller, & Jemal, 2015). Yet if detected early, CRC is 
highly curable; but because of the nature of screening recommendations and 
underutilization of screening by at risk populations, CRC remains under diagnosed at the 
localized stage. The at-risk population for CRC is generally seen as patients over the age 
of 50. However, because this screening recommendation is very broad with a low yield of 
CRC incidence in the general population (under 10%), it remains under utilized by those 
who need it and perhaps over utilized by those who may not (Roy, Backman, & 
Goldberg, 2006). A better and more personalized approach to screening guidelines will 
be needed to accurately identify patients in need of earlier or more frequent screening 
intervals rather than just advising everyone over the age of 50 to have a colonoscopy.  
 Presently, numerous genetic and exogenous factors have been identified for risk 
stratification but the utilization of these factors together to come up with a predictive 
model for colon cancer remains difficult because the interactions between these factors 
are complex and unpredictable (H. Roy et al., 2013). It is posited that utilization of a field 
effect approach, whereupon micro-environmental changes along the entire colonic 
mucosal tract are detected, in combination with the use of an accurate biomarker may be 
a more robust method of early identification of patients at a higher risk of developing 
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CRC (H. K. Roy, Backman, & Goldberg, 2006). This topic remains the crux of my thesis 
and will be revisited later in the paper. 
Colorectal Cancer Pathway 
 Colon cancer has various progression pathways determined by differing 
molecular and genetic events. The main overarching pathway is the transformation from 
a benign growth or polyp (adenomatous polyp/adenoma) in the colonic mucosa to an 
adenocarcinoma with varying degrees of invasion and lymph node metastases.  The 
adenomatous polyp is characterized by its cellular dysplasia but is still benign. However, 
as the neoplastic process continues, mutations in critical genes and other genetic 
disturbances begin to occur. In the APC/β-catenin pathway (shown in Figure 1), which 
accounts for the majority of sporadic colon cancers (>80%), the tumor suppressor 
adenomatous polyposis coli (APC) gene is initially mutated at a relatively early stage. 
Loss of APC promotes cellular proliferation through the disruption of Wnt-signaling and 
leads to further mutations such as in proto-oncogene KRAS  (Jänne & Mayer, 2000). 
Activating mutations in KRAS are seen in advanced stages and promote further growth 
and inhibition of apoptosis. In advanced stages of the adenoma-adenocarcinoma 
paradigm of CRC, many tumor suppressor genes including p53 will have accumulated 
mutations and growth occurs uninhibited (Raskov, Pommergaard, Burcharth, & 
Rosenberg, 2014).  
 Another major pathway for sporadic colorectal cancers is the microsatellite 
instability (MSI) pathway. This pathway results from mutations in DNA mismatch repair 
genes (hMLH1, hMSH2, hMSH6). Microsatellite repeats in DNA accrue as a result of 
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these mutations and lead to deficiencies in proteins regulating cell growth such as the 
pro-apoptotic Bax protein. MSI associated CRC is typically characterized by mutations in 
the BRAF oncogene, silencing of tumor suppressor genes through CpG island 
hypermethylation, as well as the presence of microsatellite instability. In contrast to the 
adenomas seen in the traditional pathway, MSI results in sessile serrated adenomas 
(SSAs) which typically have no cellular dysplasia and must be distinguished from the 
nonmalignant hyperplastic polyps (HPs) especially if found in the proximal or transverse 
colon  (Birgisson et al., 2015).  
 There are also well-described hereditary forms of colon cancer that have provided 
great insight into the progression of sporadic colon cancers. About 3-6% of all colorectal 
cancers are hereditary with a lifetime CRC risk of 70-90% for individuals possessing 
these syndromes. Lynch syndrome, or hereditary non-polyposis colorectal cancer 
(HNPCC), is characterized as an autosomal dominant disease. A germ line mutation in 
DNA mismatch repair genes exists in patients with HNPCC. This causes extensive DNA 
mismatches especially in microsatellite regions leading to microsatellite instability. 
Familial adenomatous polyposis (FAP) is also an autosomal dominant disease but results 
from germ line mutations in APC. It is diagnosed clinically with a high frequency of 
large numbers of polyps. In contrast to FAP and HNPCC, MUTYH associated polyposis 
(MAP) is an autosomal recessive disorder characterized by bi-allelic mutations in the 
base excision repair gene, MUTYH. MAP presents in a similar fashion to FAP but 
generally has significantly fewer adenomas (less than 100) (Samadder, Jasperson, & Burt, 
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2015). The pathways for these hereditary gene mutations help us understand how the 
same gene mutations in sporadic colon cancer work to potentiate the cancer. 
 Catching colon cancer at its earliest stage when it is still characterized by the 
adenomatous polyp is crucial to preventing CRC related morbidity. At this stage, removal 
of the polyps by endoscopic polypectomy will greatly decrease chances of CRC 
incidence and death (Levin et al., 2008). This fact puts into perspective the extreme 
importance of accurate and efficient colorectal cancer screening. 
 
 
  
 
Figure 1. Colon Cancer APC/β-catenin pathway: This figure illustrates the morphological changes as 
well mutational changes that occur as a hyperplastic epithelium progresses to colon adenocarcinoma. 
The APC mutation occurs early and is considered the gateway into the process. KRAS mutations lead to 
progression into the larger or more advanced adenomas (Jänne & Mayer, 2000). 
!!
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Colorectal Cancer Screening 
 Currently there are multiple recommended CRC screening tests: colonoscopy, 
flexible sigmoidoscopy, and fecal occult blood tests (FOBTs) (H. K. Roy et al., 2006). 
Flexible sigmoidoscopy (FS) is a structural examination of the distal colon and rectum 
using a colonoscope. FS’s efficacy is based around the theory that most colorectal 
adenomas and cancers are located in the distal or sigmoid section of the colon however 
because only this small section is observed, adenomas arising in the proximal or 
transverse sections will be missed. Figure 2 shows a comparison between FS and general 
colonoscopy. Fecal occult blood tests, on the other hand, rely upon the observation that 
colorectal tumors emit small amounts of blood or other tumor products that can then be 
analyzed from stool samples (Bretthauer, 2010).  
 These tests have a range of invasiveness, patient discomfort, accuracy, and cost. 
FOBT is the least invasive and the least costly but also has the lowest sensitivity due to 
the test having to find small traces of neoplastic occult blood in large samples of stool 
(Levin et al., 2008). FS is similar in accuracy and design to screening colonoscopy but 
suffers the major flaw of only screening a small portion of the colon. Recently, the use of 
FOBTs and flexible sigmoidoscopy is dropping while there has been a sharp increase in 
the use of screening colonoscopy, which is attributable to Medicaid beginning to 
reimburse screening colonoscopy in 2001 (Holden, Jonas, Porterfield, Reuland, & Harris, 
2010). However, it should be also noted that currently only FOBTs and flexible 
sigmoidoscopy have been shown via long term randomized control trials (RCTs) to 
reduce CRC incidence and mortality. It is believed that colonoscopy will show better 
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results in RCTs that have been recently started because of its higher sensitivity for 
adenomas then FOBTs and its more thorough screening of the colon in comparison to 
flexible sigmoidoscopy (Bretthauer, 2010; Zauber, 2015). 
 
 Colonoscopy screening is widely held to be the gold standard by which to assess 
other screening tests for cancer (Lieberman et al., 2012). In the United States, it is almost 
always the recommended choice of screening by gastroenterologists. It allows for 
complete structural investigation of the colon and prompt removal of the precancerous 
lesion, the adenomatous polyp (Zauber, 2015). However, various issues with screening 
Figure 2. Flexible Sigmoidoscopy vs. 
Colonoscopy: Illustration A 
demonstrates the capacity of a flexible 
sigmoidoscope for monitoring the colon. 
This illustration is even generous with 
regards to how far up the distal colon the 
scope can reach. Generally only the 
sigmoid colon and rectum are surveyed. 
Illustration B displays the reach of a 
general colonoscopy endoscope. This 
method monitors the entire colon 
including the length of the proximal and 
transverse colon. 
 Image A modified from 
http://www.hopkinsmedicine.org/gastroe
nterology_hepatology/clinical_services/b
asic_endoscopy/flexible_sigmoidoscopy.
html. Accessed March 23, 2015 
Image B modified from 
http://www.hopkinsmedicine.org/gastroe
nterology_hepatology/clinical_services/b
asic_endoscopy/colonoscopy.html. 
Accessed March 23, 2015 
 
!!
7 !
colonoscopy are preventing CRC screening rates from rising to the levels necessary to 
significantly reduce CRC incidence and mortality.  
 The underuse of screening colonoscopies on at risk patients is perhaps the largest 
problem. One issue is that the cost of colonoscopies inhibits its use by the underinsured, 
particularly those in lower socioeconomic groups (Meester et al., 2015). Another major 
factor for underuse of colonoscopy remains the fact that less than 10% of patients yield 
screen relevant neoplasms during screening (Lieberman et al., 2012). These two issues 
combined with its high invasiveness lead to vast under utilization. Yet even if everyone 
decides to submit to a colonoscopy at age 50, the healthcare system cannot support 
screening the entire population (H. K. Roy et al., 2006). In addition to underuse, there is 
also overuse whereby patients who are not likely to benefit are screened or when patients 
are having screening procedures too frequently. For instance, patients with irritable bowel 
Disease (IBD, ex. Ulcerative Colitis, Chron’s Disease, etc) symptoms are frequently 
recommended for full screening colonoscopies while the prevalence of adenomas remains 
significantly lower for this group than “average risk” patients (Lieberman et al., 2014). 
Improvements must be made to the system of performing early risk stratification so as to 
be able to efficiently utilize the limited endoscopic capacity for CRC prevention in the 
real at risk population.  
 
Increased Incidence of CRC in Younger Patients 
 Surprisingly, there has been increased incidence of CRC and CRC related 
mortality in younger patients under the age of 50. As shown in Figure 3, colon and rectal 
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cancer incidence, while declining steadily for patients over the age of 50, has seen a sharp 
rise in individuals under 50 years of age (Ahnen et al., 2014). This group of patients is 
generally not given screening colonoscopy early enough and CRC often progresses to 
advanced stages before diagnosis. An improved risk stratification method that can be 
utilized early for colonoscopy recommendation would greatly benefit patients likely to 
develop early onset CRC.   
 Currently, earlier screening is only recommended to patients with familial 
patterns of colon cancers and genetic predispositions such as familial adenomatous 
polyposis (FAP), Lynch syndrome, and MUTYH associated polyposis. These conditions 
only account for 15-20% of early onset CRC while the majority of cases remain 
etiologically undetermined (Jones et al., 2015). In these cases, there are many factors that 
would lead to late diagnosis, such as younger patients deciding not to seek care when 
symptoms present, primary care physician misdiagnosis, and lack of insurance (Ahnen et 
al., 2014). Assessing risk factors earlier in a new novel way will be necessary to decrease 
rate of early sporadic CRC incidence.  
 Lifestyle and environmental factors are currently thought to have a profound 
impact on the development of colon cancer (Anand et al., 2008). These include tobacco 
use, alcohol consumption, diet, exercise, diabetes mellitus, and obesity. And it is these 
factors in addition to underuse of screening that may explain the rise in early onset CRC. 
These factors also are the same or increased in the older age groups but because of higher 
colonoscopy screening rates the incidence rates trend downward (Ahnen et al., 2014).  
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Obesity’s Impact on Cancer 
 Obesity has become an epidemic worldwide, particularly in the United States with 
an estimated 20% of men and 25% of women being considered obese. Obesity is defined 
by a body mass index (BMI) of 30 kg/m2 or higher. Prevalence of obesity is on the rise 
with more and more individuals falling under its classification (Kopelman, 2000). This 
trend is sobering, as obesity has been linked as a major risk factor in numerous diseases. 
In particular, a recent meta-analysis of 70,000 cases of CRC found that patients with a 
Figure 3. Age-adjusted colon cancer incidence per 100,000 patients in individuals under the 
age of 50 (A) and those 50 years of age or older (B) (Ahnen et al., 2014). 
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BMI greater than 30 had a 20% greater risk of developing CRC when compared with 
patients in the normal weight range (defined by BMI <25) (Moghaddam, Woodward, & 
Huxley, 2007). Obesity has also been seen to accelerate the onset of early colorectal 
cancer, as shown in Figure 4 (Umar & Greenwald, 2009).  
 
 
 
 
 Although increasing obesity in the population is certainly having an impact on 
CRC incidence trends, the exact mechanism by which obesity increases the risk of CRC 
is unknown (Tandon, Imam, Ismail, & Castro, 2015). Adipose tissue functions as an 
Figure 4. Impact of Obesity on Early Onset CRC: This graph illustrates the increase in colon 
cancer incidence associated with obesity along with poor diet and sedentary lifestyle. It also 
points out that healthy diet, active lifestyles, and especially early detection will decrease risk of 
CRC incidence. Figure taken from Umar A and Greenwald P Cancer Epidemiol Biomarkers Prev 
2009; 18:1672-1673 
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endocrine organ and produces various factors that are collectively called adipokines. 
Adipokines can be proteins, cytokines, or hormones. These factors have many functions 
but in particular, have a profound role in modulating the inflammatory response. High 
levels of these inflammatory adipokines may be the triggers for CRC initiation 
(Comstock et al., 2014). 
 A recent study of serum adipokine levels in an adult white male cohort by 
Comstock et al. suggests that the following adipokines have the most positive correlation 
with colorectal adenoma formation: leptin, interferon-γ-inducible protein (IP-10), and 
tumor necrosis factor-α (TNFα). All three of these factors promote cellular growth and 
inhibit apoptosis through the phosphoinositol-3-kinase/Akt signaling pathway. It is clear 
then that high amounts of these adipokines may give rise to a suitable environment for 
cancer to potentiate in. However, a definitive correlation still may not exist between these 
adipokines and increased incidence of CRC since the studies did not address locally 
produced adipokines (only serum adipokines were measured) and the patient cohort was 
small and only included adult white males (Comstock et al., 2014). 
 Dysfunctional or dysbiotic gut flora compositions have also been noted in patients 
harboring CRC adenomas. Normally, bacteria in the gut exist in a symbiotic manner with 
intestinal epithelial cells. The mutually beneficial relationship allows the colon to process 
dietary polysaccharides and the bacteria benefit through the use of carbohydrates for 
energy. These bacteria also affect inflammatory response, insulin sensitivity, and 
adipokine release (Zhu, Michelle Luo, Jobin, & Young, 2011). Thus, when the 
microbiome is dysfunctional as seen in obese patients, negative changes in apoptotic 
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signaling as well as activation of cellular growth/proliferation signaling can occur 
providing a proliferative environment for cancer. This relationship is extremely complex 
because of the multiple signaling pathways that are affected as shown in Figure 5  
(Bardou, Barkun, & Martel, 2013).   
 Evidence also shows that obesity, as part of a range of environmental factors 
termed the metabolic syndrome, is heavily linked to type II diabetes. This linkage occurs 
through altered insulin sensitivity, deficient glucose metabolism, and other cardiovascular 
risk factors  (Després & Lemieux, 2006). The altered metabolism seen in metabolic 
syndrome also affects cancer through changes in the relationship between glycolysis, 
tricarboxylic acid (TCA) cycle, and mitochondrial oxidative phosphorylation (OXPHOS) 
pathways. First discovered by Otto Warburg over 90 years ago, these changes are now 
considered one of the hallmarks of cancer (Yadava, Schneider, Jerry, & Kim, 2013).  
This effect is called the Warburg effect and is described in the next section. 
 It is important to note that changes mediated through obesity and the metabolic 
syndrome can be reversed through lifestyle changes and reduction in body mass index 
(BMI). In particular, increased exercise and improvement in diet have been shown to 
decrease risk of CRC and other diseases linked to metabolic syndrome  (Boutron-Ruault, 
Senesse, Méance, Belghiti, & Faivre, 2001; Després & Lemieux, 2006).  
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Figure 5. The yellow arrows indicate how dysbiotic microbiota can affect obesity associated colon 
cancer through various pathways. This illustrates the complexity of the interactions of colon epithelial 
cells with not only gut microbiota but also with other obesity related conditions such as adipokine 
release. Also shown is how the obesity associated inflammation as well as metabolic syndrome can 
influence the progression of CRC. Image modified from Bardou M., Barkun A., and Martel M. Gut 
2013; 62:933-947  
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Warburg Effect and Cancer 
 Over 90 years ago, Otto von Warburg discovered what has been termed the 
Warburg Effect. The Warburg Effect describes the phenomena seen in tumorigenic cells 
whereby aerobic glycolysis is utilized over mitochondrial OXPHOS even in oxygen rich 
or normoxic conditions. This is strange considering that cancer cells, which are 
proliferating at high rates, need a large amount of energy in the form of adenosine tri-
phosphate (ATP). Mitochondrial OXPHOS yields much more ATP than aerobic 
glycolysis. Yet, this preferential use of aerobic glycolysis along with mitochondrial 
dysfunction is evident in many cancers (Boland et al., 2013).  
 To understand this phenomenon lets first take a look at normal energy metabolism 
in cells. Normally, glucose undergoes glycolysis in the cytosol to generate pyruvate as 
well as a small amount of ATP. Pyruvate can then enter the mitochondria to promote 
OXPHOS as well as other mitochondrial pathways or stay in the cytosol to undergo the 
lactic acid pathway via lactate dehydrogenase. In normoxic conditions (in which O2 
presence is abundant), the mitochondrial pathway predominates. Once in the 
mitochondria, pyruvate is converted into acetyl CoA through oxidative decarboxylation 
by pyruvate dehydrogenase. This rate limiting step is regulated by pyruvate 
dehydrogenase kinase, which functions to down-regulate pyruvate dehydrogenase 
through phosphorylation. If this phosphorylation does not occur, acetyl CoA can enter the 
Krebs Cycle to generate NADH and FADH2 which donate electrons to the electron 
transport chain (ETC). These electrons are passed down the ETC to eventually reduce 
respiratory oxygen into water and concurrently generate ATP through ATP synthase. The 
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ATP synthase is powered by the proton gradient formed as the electrons move down the 
chain  (Longo & Archer, 2013). This is a highly efficient process when compared to 
aerobic glycolysis, with OXPHOS producing around 30 ATP per molecule glucose and 
glycolysis only producing 2 net ATP per molecule glucose  (Yadava et al., 2013). See 
Figure 6 for an overview of this process.   
 Why then are tumorigenic cells seen to shift the flux of glucose away from the 
OXPHOS pathway and instead into various biosynthetic pathways? This question has yet 
to be answered in a satisfying manner although various hypotheses on why cancer cells 
exhibit this behavior have been suggested such as evasion of apoptosis via regulation of 
mitochondrial cytochrome c release or in response to reactive oxygen species (ROS) 
release. It is also recognized that in normal embryogenesis, hyper proliferative embryonic 
cells also utilize the Warburg effect perhaps due to biosynthetic needs for nucleosides, 
amino acids, and macromolecules. This may explain aerobic glycolysis’ role in tumor cell 
potentiation as well (Boland et al., 2013). Although it’s purpose has not fully been 
elucidated, it is clear through many studies of different cancers that mitochondrial 
dysregulation does exist in a manner consistent with the Warburg effect. In fact, the 
Warburg effect is now considered one of the eight hallmarks of cancer in Hanahan and 
Weinberg’s latest review article (Hanahan & Weinberg, 2011).   
 There are three areas of interest in Warburg: the glycolytic alterations, pyruvate 
shunting, and mitochondrial dysregulation. In regards to glycolysis, it has been seen that 
glucose transporter 1 (GLUT1) is up-regulated to increase glucose uptake by the 
cancerous cells. High glucose flux into the tumor cell is necessary to support energy 
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demands without the use of OXPHOS. Glucose is converted to pyruvate through 
glycolysis with the last step occurring via pyruvate kinase. A different spliced variant of 
pyruvate kinase, pyruvate kinase muscle 2 (PKM2) is seen expressed in both embryonic 
development and in the Warburg Effect. PKM2 is seen as a marker for aerobic glycolysis 
for Warburg. Pyruvate’s conversion to acetyl CoA via pyruvate dehyrogenase is 
regulated by pyruvate dehydrogenase kinase 1 (PDK1) which deactivates pyruvate 
dehydrogenase. Both GLUT1 and PDK1 are upregulated via hypoxia-inducible factor 1 α 
(HIF1α)  (H. Jones et al., 2015). HIF1α is transcriptional factor, which normally seeks to 
shunt pathways away from OXPHOS under low oxygen conditions. It is also important in 
promoting angiogenesis via regulation of vascular endothelial growth factor receptor 
(VEGFR). However, in normal conditions with plentiful oxygen, HIF1α is post-
translationally modified through prolyl-hydroxylation. In this state, HIF1α associates 
with the tumor suppressor protein, von Hippel-Lindau (VHL) and is subsequently 
targeted for degradation. On the flip side, in normal low oxygen conditions, mitochondria 
release reactive oxygen species (ROS) and cause the activation of HIF1α. Up regulation 
of HIF1α also occurs in normoxic conditions in tumor cells through mutations in tumor 
suppressor genes such as VHL, which contributes to the potentiation of Warburg Effect 
(DeBerardinis, Lum, Hatzivassiliou, & Thompson, 2008). It is clear then that HIF1α, 
glucose transporters, PKM2 and PDK1 are important in Warburg mediated metabolic 
dysfunction.  
 The other characteristic of Warburg is its mitochondrial dysregulation. 
Mitochondria are dynamic organelles undergoing various cycles of growth and division 
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in response to cellular demands and extracellular factors such as oxygen availability. 
Mitochondrial mass increases via replication of mitochondrial DNA (mtDNA) as well as 
increases in protein mass. Conversely mitochondria can also undergo degradation or 
mitophagy by an autophagosome. Biogenesis of mitochondria occurs via two main 
processes: fusion and fission. 
Fusion is the process by which neighboring mitochondria fuse together to form a 
continuous mitochondrial reticulum. This process is mediated by a couple factors, namely 
optic atrophy 1 GTPase protein (OPA1) in the inner mitochondrial membrane mitofusin-
1 (MFN1) and mitofusin-2 (MFN2) in the outer mitochondrial membrane as shown in 
Figure 6. MFN1 and MFN2 mediate fusion of the outer membrane while OPA1 mediates 
fusion of the inner membrane  (Longo & Archer, 2013).   
Fission on the other hand is the process in which mitochondria split into smaller 
more fragmented mitochondria. A different GTPase mediates this process, dynamein 
related protein 1 (DRP1). DRP1 is recruited from the cytosol to the outer mitochondrial 
membrane where it works to pinch off the membrane in order to split the mitochondria. It 
is an important process in biogenesis of daughter mitochondrion as well as in mitophagy 
and cellular apoptosis  (Boland et al., 2013).  
Biogenesis is seen to be upregulated in response to cellular demands, as well as 
many other factors such as mutations in tumor suppressor genes like p53 and activated 
oncogenes such as c-MYC. Currently, perioxisome proliferator activator receptor gamma 
coactivator 1 alpha (PGC1α) is thought to be the major integrator of transcriptional 
control on mitochondrial biogenesis (Boland et al., 2013).  
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In tumorigenic cells there also exists an upregulation in uncoupling protein 2 
(UCP2). UCP2 is anion carrier protein in the inner mitochondrial membrane that 
decouples ATP generation from the proton gradient, thus preventing OXPHOS. Derdak 
et. al found overexpression of UCP2 in human colon cancer cells which was postulated to 
be due to protection of cancer cells from apoptosis via suppression of mitochondrial ROS 
release. UCP2 also provides a mechanism by which a shift toward aerobic glycolysis can 
be promoted  (Derdak et al., 2008). 
Early Warburg Effect as a Biomarker   
 Getting back to the topic of finding a method to improve early colon cancer risk 
stratification, it is clear that biomarkers need to be investigated. Successful biomarkers 
have been found for other cancers such as breast cancer and prostate cancer but there is a 
profound need for finding biomarkers for early identification of sporadic cancer risk  
(Hudson, 2013). Utilization of a field effect approach may be necessary to utilize 
biomarkers through less invasive measures. The field effect model of colon 
carcinogenesis posits that the microscopic alterations in the distal colon mucosa will 
show changes indicative of an existing adenoma or increased risk of developing an 
adenoma. Previous work by Wali et al. has shown that microvascular blood in particular 
was altered in endoscopically normal mucosa  (Wali et al., 2005). This suggests that field 
carcinogenesis rather than adenomas and tumors themselves may be the key to locating 
useful biomarkers (Roy et al., 2013). In particular, it may be possible to assess 
mitochondrial and metabolic dysfunction through the use of a field carcinogenesis model 
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to perform risk stratification. 
 
 
 
 
 
Figure 6. This illustration details the various relevant biochemical pathways as well as mitochondrial 
biogenesis control. The Warburg Effect has effects on many points in this diagram: pyruvate shunting via 
PDK and HIF1, upregulation of glucose transport into the cell, and mitochondrial fission and fusion. 
Figure modified from Archer, S. New England Journal of Medicine 2013;369-2236-51 
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Aims and Objectives 
  The purpose of this thesis is to assess if a Warburg/Warburg-like effect is evident 
through select molecular markers that may possess implications for risk stratification of 
colon carcinogenesis. We hypothesized that patients with adenomas would have 
significant changes in mitochondrial mass and upregulation of certain key metabolic and 
mitochondrial genes (GLUT1, UCP2, PKM2, HIF1α, and OPA1). Furthermore, based on 
the field carcinogenesis effect, these changes could be assessed in the easily accessible 
distal colon (rectum) irrespective of the location of the colonic lesion.  
 For this study we used two rodent models for CRC as well as a patient cohort of 
approximately 80 individuals with around 40 harboring adenomas. Specifically we hope 
to achieve the following goals: 
1) Quantify changes in gene expression for glycolytic and mitochondrial 
biogenesis markers to establish a Warburg Effect in patients and rodent 
models of CRC. 
2) Quantify a change in mitochondrial mass due to Warburg effect in rectal colon 
epithelial cells for patients and rodent models of CRC. 
3) Explore the utilization of these changes as a means of early risk stratification 
for CRC. 
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METHODS 
 
Animal Studies   
The animals protocols/ animal samples used for this study were reviewed and 
approved by the Institutional Animal Care and Use Committee (IACUC) of NorthShore 
University HealthSystem (Evanston, IL). Animal housing was climate-controlled 
(ambient temperature at 25OC) and at a 12 hr light/dark cycle.  
 
Azoxymethane Rat (AOM) Model  
Twelve male rats of Fisher F-344 background were procured from Harlan Teklad 
(Madison, Wisconsin) and maintained on AIN76-A rodent chow (Harlan Teklad) with ad 
libitum access to water. These rats were randomized to either 2 weekly intraperitoneal 
injections of azoxymethane (administered at a concentration of 15mg/kg of body weight) 
or saline. Serial colonoscopies were performed on the rodents for adenoma 
detection/frequency. Rats were housed for 40 weeks and euthanized. Colons were excised 
and cleansed with ice cold phosphate saline buffer (PBS). Colonic epithelial mucosa was 
collected for genetic analysis through Real Time PCR.  
 
Polypopsis In Rat Colon Rat Model  
Six Polypopsis in Rat Colon (Pirc) Rats were obtained from Taconic Laboratories 
(Hudson, NY) at an age of roughly 10wks. These rodents have been genetically modified 
APCΔ1137 and this rodent model (partially) recapitulates the human disease FAP, however 
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can be seen as a useful model for CRC as ~80% of sporadic CRCs are attributed to APC 
truncation  (Amos-Landgraf et al., 2007). Six age-matched controls (Fisher F-344 rats 
consistent with Pirc rat background) were also obtained (Taconic Laboratories, Hudson, 
NY). Serial colonoscopies were performed on the rodents for adenoma 
detection/frequency. These animals were housed for 24 weeks and euthanized. Colons 
were excised and flushed with PBS. Colonic epithelial mucosa was obtained for Real 
Time PCR analysis.   
 
Human/Patient Studies 
Human samples were obtained with an approved Institutional Review Board 
(IRB) protocol from NorthShore University HealthSystem with informed consent. 
Patients undergoing either screening or surveillance colonoscopies were included in this 
study. Patients who received incomplete colonoscopies (failure to intubate the cecum), 
taking anti-coagulants, or other confounding factors were excluded from this study. 
Briefly, rectal biopsies were obtained during colonoscopy. Samples were collected in 
PBS and frozen for preservation and later analysis. Forty patients with no adenomas and 
thirty nine patients harboring adenomas were used for the following study. 
 
RNA and DNA Isolation   
Rat epithelial mucosa was homogenized through mechanical disruption. RNA and 
gDNA were stabilized in Trizol (Life Tech, Foster City, CA). The nucleic acids were 
isolated from these samples with RiboPure RNA Isolation Kit (Life Tech, Foster City, 
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CA). Human rectal biopsies were also homogenized by mechanical disruption and stored 
in Trizol for RNA stabilization. RNA and gDNA from human samples were isolated with 
Ribopure RNA isolation Kit for isolation. All RNA samples (animal and human) were 
quantified with NanoDrop (Fisher Scientific, Hanover Park, IL).  
 
Polymerase Chain Reaction (PCR)  
  Quantified RNA was synthesized using the High Capacity cDNA Synthesis Kit 
(Life Tech, Foster City, CA). cDNA synthesis was facilitated with Step-One Plus 
Thermocycler (Life Tech, Foster City, CA). cDNA and gDNA was prepared  for Real 
Time PCR using Taqman Gene Expression Assay primers (for each respected marker) 
and Real Time Universal Master Mix. For quantification of mt-NADH Dehydrogenase 
(mtND1), 18s gDNA was used as control. For all other markers, beta actin was used as a 
loading control. Concentrations of these markers were assessed with comparative (2-ΔΔCt) 
and quantitative Real Time PCR data analysis was performed using RQ Manager 1.2.1 
(Life Tech, Foster City, CA).   
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RESULTS 
 
Mitochondrial Mass in AOM Rats and Patients 
 Mitochondrial mass was evaluated via quantification of the expression of a 
common mitochondrial DNA fragment, mtND1. This was normalized with the expression 
of nuclear DNA, 18s gDNA. In the AOM rat model, we found a significant ~2.4-fold 
(p≤0.024) increase in expression in AOM rats versus the control rats as shown in Figure 
7. For this study, 10 AOM rats and 6 control rats were used. This trend was also seen in 
human rectal biopsies, with a ~1.76-fold (p≤0.05) increase in patients harboring 
adenomas as shown in Figure 8.   
!
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Figure 7. AOM rats show ~2.4-fold increase in expression of mtND1 (p≤0.024) over 
expression in control rats injected with only saline. Std. error bars are also shown. 
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OPA1 Expression in Pirc Rats and Patients 
 Expression of OPA1 was quantified in both the Pirc rat model as well in human 
rectal biopsies. In Pirc rats, a ~1.67-fold change in expression of OPA1 was observed 
(p≤0.027) as shown in Figure 9. Patients with adenomas showed a ~1.52-fold change in 
expression when compared to patients with no adenomas (p≤0.045) as shown in Figure 
10. 
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Figure 8. Patients with adenomas showed a ~1.76-fold increase in expression of 
mtND1 (p≤0.024) indicating increased mitochondrial mass. Std. error bars are also 
shown. 
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Figure 9. PIRC rats show ~1.67-fold increase in expression of OPA1 (p≤0.027) over 
expression in control rats. Std. error bars are also shown. 
Figure 10. Patients with adenomas showed a ~1.52-fold increase in expression of 
OPA1 (p≤0.045) indicating increased mitochondrial fusion. Std. error bars are also 
shown. 
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UCP2 Expression in Pirc Rats and Patients 
 Expression of UCP2 was quantified in both the Pirc rat model as well in human 
rectal biopsies. In Pirc rats, a ~2.01-fold change in expression of UCP2 was observed 
(p≤0.05) as shown in Figure 11. Patients with adenomas showed a ~2.65-fold change in 
expression when compared to patients with no adenomas (p≤0.01) as shown in Figure 
12. 
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Figure 11. PIRC rats show ~2.01-fold increase in expression of UCP2 (p≤0.05) over 
expression in control rats. Std. error bars are also shown. 
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HIF1α Expression in Patients 
 Expression of HIF1α was measured in the patient rectal biopsies. Patients with 
adenomas showed ~1.97-fold increase in HIF1α expression (p≤0.01) as shown in Figure 
13.  
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Figure 12. Patients with adenomas showed a ~2.65-fold increase in expression of 
UCP2 (p≤0.01) indicating uncoupling of ATP production in the mitochondria. Std. 
error bars are also shown. 
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GLUT1 Expression in Patients 
 Expression of GLUT1 was measured in the patient rectal biopsies. Patients with 
adenomas showed ~3.46-fold increase in GLUT1 expression (p≤0.01) as shown in 
Figure 14.  
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Figure 13. Patients with adenomas showed a ~1.97-fold increase in expression of 
HIF1α (p≤0.01) indicating potentiation of Warburg like effects. Std. error bars are 
also shown. 
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PKM2 Expression in Patients 
 Expression of PKM2 was measured in the patient rectal biopsies. Patients with 
adenomas showed ~1.94-fold increase in PKM2 expression (p≤0.01) as shown in Figure 
15.  
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Figure 14. Patients with adenomas showed a ~3.46-fold increase in expression of 
GLUT1 (p≤0.01) indicating increased cellular glucose intake. Std. error bars are also 
shown. 
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Figure 15. Patients with adenomas showed a ~1.94-fold increase in expression of 
PKM2 (p≤0.01) indicating increased aerobic glycolysis. Std. error bars are also 
shown. 
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DISCUSSION 
 
The search for biomarkers for cancer phenotypes and in high risk patients is 
strongly sought out for translational detective measures and personalized 
chemoprevention as well as chemotherapies. With credit to innovations and findings for 
early CRC detection, prognosis has markedly improved over the past 20 years with the 
use of better screening procedures and administration of non-steroidal anti-inflammatory 
drugs (NSAIDs). CRC risk has been reduced by a significant 30-50%. However, the 
incidence of CRC related mortalities in the United States is only preceded by that of lung 
cancer in American men and women combined (Siegel, Miller, & Jemal, 2015). This 
underscores the need for more definitive/effective measures for screening and risk 
stratification. The prevalence of cancer risk in our society has focused much attention on 
metabolic disease, where diabetes and obesity status have been the attributing platforms. 
The changes in metabolic demand as well as its pathway are criteria for carcinogenesis. 
One of the hallmarks of cancer, the Warburg Effect, was discovered in the first half of 
last century and provides potential insight in the understanding of progression and 
malignant features in colon cancer.  To cover the first aims of this thesis, we chose to 
explore the expression of select molecular markers well established in the Warburg Effect 
in patient rectal biopsy samples. We compared patients possessing detectable adenomas 
versus control patients with no significant colonoscopic findings. Patients harboring 
lesions (depending on factors such as size, histological features and location) are 
presented as the at risk population for CRC.   
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 To establish that early Warburg/Warburg-like effects exist in the field 
carcinogenesis model of CRC we first looked at changes in expression of glycolytic 
genes. For aerobic glycolysis to achieve enough glucose flux to generate sufficient 
energy in the absence of OXPHOS, glucose uptake via glucose transporters must be 
upregulated. We found a significant ~3.53-fold change in GLUT1 in patients with 
adenomas compared to patients without. GLUT1 regulation is intrinsically tied with 
HIF1α expression, which we looked at next.   
 HIF1α is extremely important for cellular response to hypoxic conditions, 
mediating angiogenesis through vascular endogenic growth factor (VEGF) as well as 
other functions to fulfill metabolic demands. In the case of Warburg effect, effects 
normally associated with hypoxic conditions are seen in normoxic conditions. In our 
studies, we found that HIF1α was significantly overexpressed in the patient cohort 
(~1.98-fold change) suggesting presence of the Warburg effect. HIF1α upregulates 
PKM2 and GLUT1, which are both suggestive of aerobic glycolysis  (Semenza, 2011). 
To add to this we found that PKM2 was also overexpressed in the patient cohort (~1.94-
fold change). PKM2 is recognized through many studies as a marker of the Warburg 
effect through its role in shunting pyruvate away from the oxidative phosphorylation 
pathway. These findings are strongly suggestive of a Warburg or Warburg-like 
phenomena in our precancerous at risk patients. 
To further explore the Warburg effect in our patient studies, we choose to 
examine mitochondrial changes in patient rectal biopsies. It is understood the there is 
reduced OXPHOS in malignant cells, however the cancer implications in mitochondrial 
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changes (response to ROS, shunting from OXPHOS to aerobic glycolysis and other 
metabolic pathways) remain to be fully elucidated. We therefore coupled our human 
studies with the well-established rodent model of CRC, the AOM-treated rat. 
 Mitochondrial mass was seen in our studies to be increased via both increased 
levels of mitochondrial DNA and increased levels of the major mitochondrial fusion 
gene, OPA1. The measurement of mtND1 gene fragment in mtDNA is commonly used to 
establish a mitochondrial copy number and give relative mitochondrial mass (Lin et al., 
2012). In our studies, we found marked overexpression in both the AOM rat model 
(~2.01-fold change) as well as in our patient population (~1.76-fold change). However, 
the relationship between a mitochondrial mass increase and the increased aerobic 
glycolysis in Warburg effect seems counterintuitive at first glance. If mitochondrial 
OXPHOS is downregulated, why then would mitochondrial mass be increasing? But it 
must also be noted that mitochondrial mass increase and mitophagy exist in a balance in 
normal cells  (Chourasia, Boland, & Macleod, 2015). In a tumorigenic state, cancer cells 
must evade apoptosis and it is possible that inhibiting degradation of mitochondria 
through mitophagy might prevent this apoptosis. This evasion of apoptosis could also be 
the result of increased mass of mitochondria attenuating the apoptotic qualities of cancer 
induced mtDNA mutations via complementation  (Youle & van der Bliek, 2012). 
Another important factor is the presence of high cellular levels of reactive oxygen species 
(ROS) in tumor driven cancer. ROS is primarily produced in the mitochondria and is 
believed to be critical in tumor cell proliferation. Importantly, ROS is necessary for 
HIF1α stabilization, which allows for GLUT1 and PKM2 upgregulation (Hamanaka & 
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Chandel, 2010). Increased mass may generate the ROS necessary to potentiate the 
Warburg/Warburg-like effects.  
 Along with mitochondrial mass, expression of the mitochondrial fusion GTPase, 
OPA1 was studied. OPA1 showed a modest increase in both patients (~1.52-fold change) 
and the Pirc rat model (~1.67-fold change). In hypoxic states, mitochondria increase their 
OXPHOS capacity through increased fusion. However, in the normoxic conditions of 
Warburg phenomena, increased OPA1 may be suggestive of cells trying to recover 
OXPHOS in the face of increased aerobic glycolysis and mitochondrial dysfunction  
(Tondera et al., 2009). Secondly, Frezza et. al found that OPA1 protected cells from 
apoptosis by preventing release of cytochrome c from the mitochondria  (Frezza et al., 
2006). This may be another anti-apoptotic factor related to the Warburg effect. 
 Pyruvate utilization by the mitochondria is not only for use in oxidative 
phosphorylation but also necessary for other biosynthetic pathways such as the 
production of acetyl CoA for use in fatty acid biosynthesis. Acetyl CoA normally can 
condense with oxaloacetate to form citrate, allowing it to be transported out of the 
mitochondria via a shuttle. Once in the cytosol, citrate is converted back to acetyl CoA 
via ATP citrate lyase. Inhibition of this cytosolic enzyme was found to prevent cellular 
proliferation as well as fatty acid biosynthesis via pyruvate derived acetyl CoA (R. Jones 
& Thompson, 2009). Thus, cancer cells may need these mitochondrial biosynthetic 
pathways for proliferation even when OXPHOS is not needed.  
 Lastly, UCP2 expression was analyzed to show that the electron transport chain 
was indeed dysfunctional. We found overexpression in both the Pirc rat model (~2.01-
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fold change) as well as in the patient cohort (~2.65-fold change). UCP2 promotes 
glycolysis as it uncouples the electron transport chain from ATP production via proton 
leak as acting as a pyruvate transporter thereby shunting pyruvate out of the 
mitochondria. It also regulates high levels of ROS preventing apoptosis from high 
oxidative stress  (Baffy, 2010). 
  These findings in patients with neoplastic lesions speculate changes in 
mitochondrial mass, morphology and dynamics. However these patients are classified as 
at risk, where not all adenomas will undergo malignant transformation. Additionally, 
cosegregating factors (smoking, diabetes, family history) were not accounted for. We also 
did not analyze the actual activity of the proteins and only looked at the relative 
quantities of their mRNA transcripts.  
 In summary we have shown an early Warburg-like effect in the rectal mucosa of 
patients possessing adenomas through established metabolic markers. We propose an 
increased mitochondrial mass in both human and animal studies and changes in 
mitochondrial dysfunction associated genes, which may support increase in mass as well 
as fusion. The metabolic implications of colon cancer risk have been of great interest 
with diabetes and BMI status being shown as risk factors. Our results of a Warburg-like 
phenomena in the premalignant colon can start to reveal the mitochondrial changes in 
colon field carcinogenesis, inducing further studies in the potential of these changes as 
CRC biomarkers, mitochondria-mediated Warburg effects, and in targeting these markers 
for chemoprevention.   
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